BIOMAT Database Logo BIOMAT Database Logo

Corrigendum to "Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate". 2018

Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Deutsche Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin, Germany.

[This corrects the article DOI: 10.1155/2018/1374821.].

UI MeSH Term Description Entries

Related Publications

Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
December 2016, Expert opinion on drug safety,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
November 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
The Selective Progesterone Receptor Modulator, Ulipristal Acetate, in the Management of Symptomatic Uterine Fibroids.
January 2015, Journal of minimally invasive gynecology,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
April 2017, The Cochrane database of systematic reviews,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
January 2020, International journal of environmental research and public health,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
[Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
March 2013, Ginekologia polska,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
The potential of selective progesterone receptor modulators for the treatment of uterine fibroids.
January 2014, Expert review of endocrinology & metabolism,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Medical treatment with ulipristal acetate for uterine fibroids: Will it be resurrected?
July 2021, Fertility and sterility,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids.
August 2021, Journal of clinical medicine,
Thomas Rabe, and Nicole Saenger, and Andreas D Ebert, and Thomas Roemer, and Hans-Rudolf Tinneberg, and Rudy Leon De Wilde, and Markus Wallwiener
Ulipristal acetate as a treatment option for uterine fibroids.
December 2017, Przeglad menopauzalny = Menopause review,
Copied contents to your clipboard!